ALK's Q1 better than predicted on top and bottom line
Allergy firm ALK upgrades its financial outlook for the rest of the year following a first quarter that exceeded expectations.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Danish pharmaceutical company ALK managed to do better than predicted in the first three months of the year measured by income as well as revenue.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK gains important approval on difficult US market
For subscribers
.jpg&w=384&q=75)
